TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04092621
Drug: Rate-control therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
Study: NCT01247870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01960114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
Study: NCT01256372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; intravenous infusion
Study: NCT00271466
Drug: DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04348383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 250 cc every 6 hours for 7 or15 days
Study: NCT02874248
Drug: 15 mg E4/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
Study: NCT02874248
Drug: 30 mg E4/6 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
Study: NCT02874248
Drug: Visually matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
Study: NCT02874248
Drug: 75 mg E4/15 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
Study: NCT00451555
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT01141153
Drug: Acetylsalicylic Acid + clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.
Study: NCT02469077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study: NCT01040403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04697641
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice a day for two weeks
Study: NCT01284634
Drug: GWP42003 200 mg/day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Study: NCT01284634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
Study: NCT02946450
Drug: Other: Not applicable-observational study
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01732588
Drug: 120 mg OZ439 caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
Study: NCT00784277
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule for 14 days
Study: NCT00784277
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules 2 x a day for 28 days
Study: NCT00187135
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline
Study: NCT00187135
Drug: L.M.X4
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
Study: NCT01072396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
Study: NCT04299971
Drug: Methotrexate Tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead.
Study: NCT00309621
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01878188
Drug: BC-819/PEI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation
Study: NCT01865175
Drug: ionic iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
Study: NCT00475735
Drug: MK0249
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
Study: NCT00475735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
Study: NCT01076322
Drug: Meptin® Swinghaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)
Study: NCT01076322
Drug: Ventolin® MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)
Study: NCT00510783
Drug: Fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
Study: NCT01920399
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
Study: NCT01391533
Drug: SAR125844
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT02299414
Drug: Anti-hypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
Study: NCT00224809
Drug: Angiotensin-Converting Enzyme Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00224809
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02857309
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT using standard heart failure (HF) drugs
Study: NCT02277587
Drug: Conventional glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets: 20-25-30- 37.5 mg
Study: NCT01591655
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of vehicle into the study eye QID for 14 days.
Study: NCT00024102
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
Study: NCT00890214
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
Study: NCT00812825
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
Study: NCT00812825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
Study: NCT00812825
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
Study: NCT01940692
Drug: 1.5g intravenous Exacyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of 1.5g Exacyl preoperatively
Study: NCT01940692
Drug: 3.0g intra-articular Exacyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g Intra-articular Exacyl administration postoperatively
Study: NCT03078751
Drug: Adjuvant endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
Study: NCT03078751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth.
Study: NCT03090893
Drug: ATryn continuous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: replenish serum thrombin levels
Study: NCT01889277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984399
Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
Study: NCT00513461
Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01176006
Drug: Cyclophosphamide(CTX, Cytoxan)
Normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
Study: NCT02893371
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to all dosages and delivery forms.
Study: NCT02893371
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to all dosages and delivery forms.
Study: NCT02893371
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to all dosages and delivery forms.
Study: NCT03078907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching film coated tablets
Study: NCT02812251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered.
Study: NCT03030105
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT03030105
Drug: BPN14770 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00016978
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00016978
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00016978
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01177228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT03390933
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
Study: NCT01605435
Drug: Ghrelin Group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Study: NCT01605435
Drug: Ghrelin Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Study: NCT00466622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets x 2 daily. Orally from Weifa
Study: NCT04705883
Drug: Prasterone (DHEA), Micronized
Normalized name: prasterone (DHEA), micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
Study: NCT01101139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: single intravenous injection Saline 0.9%
Study: NCT03027505
Drug: Ready to Use Therapeutic Food (RUTF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day
Study: NCT01013532
Drug: placebo of aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: same size and shape of active aspirin 100mg
Study: NCT02242240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02522130
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral treatment
Study: NCT03219255
Drug: RELVAR 100 ELLIPTA
Normalized name: ECLIPTA PROSTRATA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
Study: NCT00747058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02682225
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
Study: NCT02682225
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
Study: NCT04510103
Drug: Moisturizer A, F#9155-005
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
Study: NCT00074178
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00074178
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01076088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets to sitagliptin or metformin for 24 weeks.
Study: NCT00516750
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00516750
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02919579
Drug: Placebo (Intranasal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
Study: NCT02919579
Drug: Placebo (Oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
Study: NCT03983850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
Study: NCT00389090
Drug: Temozolomide and O6-Benzylguanine
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: O6BG + Temozolomide
Study: NCT04566926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive matching placebo.
Study: NCT00506922
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
Study: NCT00823004
Drug: recombinant FSH or hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant FSH or hMG 300-450 IU/day
Study: NCT03474042
Drug: GLPG2737
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
Study: NCT03474042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
Study: NCT00352053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF Placebo administered orally, daily + OBR
Study: NCT00393198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
Study: NCT04015596
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed by weight (10mg/kg), twice daily, for 8 weeks
Study: NCT01271153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
Study: NCT02683213
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20mg once daily for 6 months.
Study: NCT02683213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT02884219
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Study: NCT02884219
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Study: NCT03082196
Drug: Test varnish
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of test varnish to the teeth 4 times per year.
Study: NCT03082196
Drug: Standard varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of test varnish to the teeth 4 times per year
Study: NCT02137239
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04313790
Drug: Heparin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)